Molecular Basis of Live-Attenuated Influenza Virus

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  He, Wen ^a,b   Wang, Wei ^a,c,d   Han, Huamin ^a   Wang, Lei ^a,c   Zhang, Ge ^a,c   Gao, Bin ^a,d  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b Hebei Key Laboratory of Medical Biotechnology   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^d UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA POLYMERASE; UNCLASSIFIED DRUG; VIRUS ENZYME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOASSAY; CONTROLLED STUDY; DNA MODIFICATION; EMBRYO; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA VIRUS A H1N1; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PB1 GENE; PB2 GENE; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; RNA SYNTHESIS; TEMPERATURE SENSITIVITY; VIRUS ATTENUATION; VIRUS GENE; VIRUS GENOME; VIRUS IDENTIFICATION;

ANIMALS; CELL LINE; GENE EXPRESSION REGULATION, VIRAL; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED C57BL; MUTATION; ORTHOMYXOVIRIDAE INFECTIONS; RNA REPLICASE; RNA, VIRAL; VACCINES, ATTENUATED; VIRAL PROTEINS;

HUMAN INFLUENZA VIRUS; ORTHOMYXOVIRIDAE;

EID: 84875443904     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060413     Document Type: Article

References (32)

1. WHO (2003) Fact sheet number 211. influenza. WHO Fact sheets.
2. Gendon Iu Z, (2001) [Live cold-adapted reassortant influenza vaccines]. Vopr Virusol 46: 5-12.
3. Cha TA, Kao K, Zhao J, Fast PE, Mendelman PM, et al. (2000) Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial. J Clin Microbiol 38: 839-845.
4. Palese P, Garcia-Sastre A, (2002) Influenza vaccines: present and future. J Clin Invest 110: 9-13.
5. Leroux-Roels I, Leroux-Roels G, (2009) Current status and progress of prepandemic and pandemic influenza vaccine development. Expert Rev Vaccines 8: 401-423.
6. Lambert LC, Fauci AS, (2010) Influenza vaccines for the future. N Engl J Med 363: 2036-2044.
7. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, et al. (2009) Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 58: 1-52.
8. Palese P, Zavala F, Muster T, Nussenzweig RS, Garcia-Sastre A, (1997) Development of novel influenza virus vaccines and vectors. J Infect Dis 176Suppl 1: S45-49.
9. Murphy BR, Coelingh K, (2002) Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol 15: 295-323.
10. Tannock GA, Paul JA, Barry RD, (1984) Relative immunogenicity of the cold-adapted influenza virus A/Ann Arbor/6/60 (A/AA/6/60-ca), recombinants of A/AA/6/60-ca, and parental strains with similar surface antigens. Infect Immun 43: 457-462.
11. Jin H, Lu B, Zhou H, Ma C, Zhao J, et al. (2003) Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. Virology 306: 18-24.
12. Lau YF, Santos C, Torres-Velez FJ, Subbarao K, (2011) The magnitude of local immunity in the lungs of mice induced by live attenuated influenza vaccines is determined by local viral replication and induction of cytokines. J Virol 85: 76-85.
13. Ghendon YZ, Polezhaev FI, Lisovskaya KV, Medvedeva TE, Alexandrova GI, et al. (1984) Recombinant cold-adapted attenuated influenza A vaccines for use in children: molecular genetic analysis of the cold-adapted donor and recombinants. Infect Immun 44: 730-733.
14. Kendal AP, (1997) Cold-adapted live attenuated influenza vaccines developed in Russia: can they contribute to meeting the needs for influenza control in other countries? Eur J Epidemiol 13: 591-609.
15. Mallory RM, Malkin E, Ambrose CS, Bellamy T, Shi L, et al. (2010) Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials. PLoS One 5: e13755.
16. Miotto O, Heiny AT, Albrecht R, Garcia-Sastre A, Tan TW, et al. (2010) Complete-proteome mapping of human influenza A adaptive mutations: implications for human transmissibility of zoonotic strains. PLoS One 5: e9025.
17. Boivin S, Cusack S, Ruigrok RW, Hart DJ, (2010) Influenza A virus polymerase: structural insights into replication and host adaptation mechanisms. J Biol Chem 285: 28411-28417.
18. Neumann G, Kawaoka Y, (2004) Reverse genetics systems for the generation of segmented negative-sense RNA viruses entirely from cloned cDNA. Curr Top Microbiol Immunol 283: 43-60.
19. Subbarao EK, Park EJ, Lawson CM, Chen AY, Murphy BR, (1995) Sequential addition of temperature-sensitive missense mutations into the PB2 gene of influenza A transfectant viruses can effect an increase in temperature sensitivity and attenuation and permits the rational design of a genetically engineered live influenza A virus vaccine. J Virol 69: 5969-5977.
20. Klimov AI, Egorov AY, Gushchina MI, Medvedeva TE, Gamble WC, et al. (1995) Genetic stability of cold-adapted A/Leningrad/134/47/57 (H2N2) influenza virus: sequence analysis of live cold-adapted reassortant vaccine strains before and after replication in children. J Gen Virol 76 (Pt 6): 1521-1525.
21. Isakova-Sivak I, Chen LM, Matsuoka Y, Voeten JT, Kiseleva I, et al. (2011) Genetic bases of the temperature-sensitive phenotype of a master donor virus used in live attenuated influenza vaccines: A/Leningrad/134/17/57 (H2N2). Virology 412: 297-305.
22. Belyakov IM, Ahlers JD, (2009) What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J Immunol 183: 6883-6892.
23. Zakay-Rones Z, (2010) Human influenza vaccines and assessment of immunogenicity. Expert Rev Vaccines 9: 1423-1439.
24. Ambrose CS, Luke C, Coelingh K, (2008) Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Influenza Other Respi Viruses 2: 193-202.
25. Fleischer B, Becht H, Rott R, (1985) Recognition of viral antigens by human influenza A virus-specific T lymphocyte clones. J Immunol 135: 2800-2804.
26. Kreijtz JH, Bodewes R, van Amerongen G, Kuiken T, Fouchier RA, et al. (2007) Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 25: 612-620.
27. Nguyen HH, Moldoveanu Z, Novak MJ, van Ginkel FW, Ban E, et al. (1999) Heterosubtypic immunity to lethal influenza A virus infection is associated with virus-specific CD8(+) cytotoxic T lymphocyte responses induced in mucosa-associated tissues. Virology 254: 50-60.
28. O'Neill E, Krauss SL, Riberdy JM, Webster RG, Woodland DL, (2000) Heterologous protection against lethal A/HongKong/156/97 (H5N1) influenza virus infection in C57BL/6 mice. J Gen Virol 81: 2689-2696.
29. Mendelman PM, Rappaport R, Cho I, Block S, Gruber W, et al. (2004) Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/2002-like H3N2 antigenic variant strain. Pediatr Infect Dis J 23: 1053-1055.
30. Toyoda T, Adyshev DM, Kobayashi M, Iwata A, Ishihama A, (1996) Molecular assembly of the influenza virus RNA polymerase: determination of the subunit-subunit contact sites. J Gen Virol 77 (Pt 9): 2149-2157.
31. A.I Klimov, I.V Kiseleva, G.I Alexandrova, N.J Cox, (2001) Genes coding for polymerase proteins are essential for attenuation of the cold-adapted A/Leningrad/134/17/57 (H2N2) influenza virus. International Congress Series 1219: 955-959.
32. He W, Han H, Wang W, Gao B, (2011) Anti-influenza virus effect of aqueous extracts from dandelion. Virol J 8: 538.